Financial Analysis: Vyome (HIND) & The Competition

Vyome (NASDAQ:HIND) is one of 27 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its rivals? We will compare Vyome to related companies based on the strength of its dividends, analyst recommendations, institutional ownership, profitability, earnings, valuation and risk.

Profitability

This table compares Vyome and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-423.39%	-166.02%
Vyome Competitors	-569.68%	-122.96%	-53.63%

Earnings & Valuation

This table compares Vyome and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Vyome	$8.01 million	-$7.13 million	-0.02
Vyome Competitors	$61.19 million	-$32.64 million	5.16

Vyome’s rivals have higher revenue, but lower earnings than Vyome. Vyome is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Vyome has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Vyome’s rivals have a beta of 1.80, indicating that their average stock price is 80% more volatile than the S&P 500.

Insider and Institutional Ownership

22.1% of Vyome shares are owned by institutional investors. Comparatively, 19.3% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by institutional investors. 33.0% of Vyome shares are owned by insiders. Comparatively, 19.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Vyome and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1	0	2	0	2.33
Vyome Competitors	80	82	161	7	2.29

Vyome currently has a consensus price target of $15.00, indicating a potential upside of 435.71%. As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 44.47%. Given Vyome’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Vyome is more favorable than its rivals.

Summary

Vyome beats its rivals on 7 of the 13 factors compared.

Vyome Company Profile

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.